Li Ying, Meng Linxia, Gong Liyan, Wang Xiao, Yang Xiaoding, Li Tao
Department of Ophthalmology, Ziyang Central Hospital, Sichuan, 641300, China.
Ziyang Key Laboratory of Ophthalmology, Ziyang Central Hospital, Sichuan, 641300, China.
BMC Ophthalmol. 2024 Dec 3;24(1):521. doi: 10.1186/s12886-024-03785-z.
To explore the clinical efficacy of modified limbal stem cell transplantation(Modified LSC transplantation) and bandage contact lens(BCL) implantation in pterygium surgery.
A total of 479 patients with primary pterygium who were admitted to our hospital from March 2019 to March 2023 were randomly divided into three groups: the normal group (Group A: 89 patients), the control group (Group B: 195 patients), and the modified group (Group C: 195 patients). Each group received different intervention measures. Group A did not undergo surgical treatment and were required to follow up as outpatients. Group B received LSC transplantation combined with interrupted suturing plus BCL, whereas Group C received modified LSC transplantation combined with BCL. The degree of corneal irritation symptoms, wound healing and graft status under slit lamp, incidence and recurrence rate of complications, tear film rupture time, tear secretion test, intraocular pressure, ocular surface inflammation response(IL-1β, PGE2, TNF-α, VEGF), and visual quality were compared and analyzed at various time points after surgery.
Compared with those in the Group B, patients in the Group C experienced faster normalization of corneal epithelium recovery, fewer corneal irritation symptoms, and better wound healing. The break-up time (BUT) of the tear film at 1 week to 1 year postoperatively was significantly greater in the Group C than Group B, with values approaching those of Group A by 3 months (P < 0.05). The Schirmer test results revealed a similar trend to that of the BUT. Further analysis of intraocular pressure (IOP) at different time points revealed no significant differences among the three groups at postoperative Day 1. However, due to the use of corticosteroid eye drops postoperatively, IOP was greater in both the Group B(17.24 ± 2.12 mmHg) and Group C (17.02 ± 2.37 mmHg) than Group A (13.92 ± 1.57 mmHg) at 1 week. By 1 month, Group C had a lower IOP (15.77 ± 1.63 mmHg) than Group B(17.78 ± 2.41 mmHg). There were no significant differences in IOP among the three groups from 3 months to 1 year (P > 0.05). The ELISA results indicated that the expression levels of the ocular surface inflammatory factors IL-1β, TNF-α, PEG2, and VEGF in the Group C were lower than those in Group B from 1 week to 1 year post surgery. Under both natural light and low-light conditions (spatial frequency/6 cd), Group C had better best-corrected visual acuity and contrast sensitivity than Group B at 1 week to 1 year postoperatively. Additionally, Group C had lower corneal higher-order aberrations (including astigmatism, spherical aberrations, and total higher-order aberrations) and superior vision-related quality of life scores at 1 year postoperatively than Group B, with statistically significant differences (P < 0.05).
Modified LSC transplantation combined with BCL implantation provided superior treatment outcomes for patients with pterygium, which was worthy of further clinical promotion.
探讨改良角膜缘干细胞移植(改良LSC移植)联合绷带式角膜接触镜(BCL)植入术在翼状胬肉手术中的临床疗效。
选取2019年3月至2023年3月我院收治的479例原发性翼状胬肉患者,随机分为三组:正常组(A组:89例)、对照组(B组:195例)和改良组(C组:195例)。每组采取不同的干预措施。A组未接受手术治疗,要求门诊随访。B组接受LSC移植联合间断缝合加BCL,而C组接受改良LSC移植联合BCL。比较分析术后各时间点角膜刺激症状程度、裂隙灯下伤口愈合及植片情况、并发症发生率及复发率、泪膜破裂时间、泪液分泌试验、眼压、眼表炎症反应(IL-1β、PGE2、TNF-α、VEGF)及视觉质量。
与B组相比,C组患者角膜上皮恢复正常更快,角膜刺激症状更少,伤口愈合更好。术后1周1年,C组泪膜破裂时间(BUT)明显长于B组,3个月时接近A组(P < 0.05)。泪液分泌试验结果与BUT趋势相似。进一步分析不同时间点眼压,术后第1天三组间无显著差异。然而,由于术后使用糖皮质激素滴眼液,1周时B组(17.24 ± 2.12 mmHg)和C组(17.02 ± 2.37 mmHg)眼压均高于A组(13.92 ± 1.57 mmHg)。1个月时,C组眼压(15.77 ± 1.63 mmHg)低于B组(17.78 ± 2.41 mmHg)。术后3个月至1年三组眼压无显著差异(P > 0.05)。ELISA结果表明,术后1周1年,C组眼表炎症因子IL-1β、TNF-α、PEG2和VEGF表达水平低于B组。术后1周~1年,在自然光和弱光条件下(空间频率/6 cd),C组最佳矫正视力和对比敏感度均优于B组。此外,术后1年,C组角膜高阶像差(包括散光、球差和总高阶像差)更低,视觉相关生活质量评分高于B组,差异有统计学意义(P < 0.05)。
改良LSC移植联合BCL植入术治疗翼状胬肉患者疗效更佳,值得进一步临床推广。